{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:06:11Z","timestamp":1789679171526,"version":"4.0.1"},"reference-count":24,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: With advances in antiretroviral therapy for HIV treatment, newer drug combinations provide improved efficacy, safety, and compliance. This study evaluates switching to a regimen of doravirine (DOR), tenofovir disoproxil fumarate (TDF), and lamivudine (3TC) in a cohort of people living with HIV (PLWH). Methods: this Italian retrospective study included 426 PLWH who switched from rilpivirine (RPV)\/TDF\/emtricitabine (FTC) to DOR\/3TC\/TDF. The analysis focused on treatment effectiveness, safety, and metabolic and renal markers. Results: this study reports a treatment failure (defined as virological failure or discontinuation of the regimen) rate of 2.34% (95% confidence interval, 1.28\u20134.50%), with significant improvement in CD4 counts (+49.93 cells\/\u00b5L, p &lt; 0.001). Notably, the switch to DOR\/3TC\/TDF did not result in adverse metabolic effects or significant changes in renal function. Analysis of lipid profiles showed stabilization in the majority of PLWH. Conclusions: this study indicates that switching to a DOR\/3TC\/TDF from RPV\/TDF\/FTC is an effective and well-tolerated option for PLWH, with benefits in terms of maintaining viral suppression, CD4 count recovery, and metabolic health, without evidence of renal impairment. These results support the continued use of DOR\/3TC\/TDF as part of HIV treatment strategies and highlight the need for ongoing research to refine ART regimens for different populations.<\/jats:p>","DOI":"10.3390\/ph17121706","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:40:56Z","timestamp":1734493256000},"page":"1706","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness and Tolerability of DOR\/3TC\/TDF in Experienced People with HIV Switching from RPV\/FTC\/TDF: A Retrospective, Single Center Cohort Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-6917","authenticated-orcid":false,"given":"Stefania","family":"Cicalini","sequence":"first","affiliation":[{"name":"Systemic and Immune Depression-Associated Infections Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6743-4001","authenticated-orcid":false,"given":"Simone","family":"Lanini","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-2623","authenticated-orcid":false,"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bellagamba","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6944-0686","authenticated-orcid":false,"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-662X","authenticated-orcid":false,"given":"Ilaria","family":"Mastrorosa","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-7504","authenticated-orcid":false,"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-0045","authenticated-orcid":false,"given":"Rozenn","family":"Esvan","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Plazzi","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Ottou","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Grilli","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"De Zottis","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Fusto","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8361-9605","authenticated-orcid":false,"given":"Jessica","family":"Paulicelli","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-4684","authenticated-orcid":false,"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[{"name":"Viral Immunodeficiencies Unit, Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/QAD.0000000000003245","article-title":"Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain","volume":"36","author":"Kauppinen","year":"2022","journal-title":"AIDS"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3851\/IMP3171","article-title":"Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial","volume":"23","author":"Yao","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and Metabolic Changes After Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV: A Cohort Study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"ref_5","unstructured":"(2024, June 20). European AIDS Clinical Society Guidelines, v. 12.0. Available online: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","article-title":"Brief Report: Switching to DOR\/3TC\/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial","volume":"87","author":"Kumar","year":"2021","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/aid.2022.0058","article-title":"Efficacy and Safety of Doravirine-Based Regimens in Real Life: A Prospective Monocentric French Study","volume":"38","author":"Garcia","year":"2022","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/QAI.0000000000003248","article-title":"Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment-Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study","volume":"94","author":"Poliseno","year":"2023","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e29855","DOI":"10.1097\/MD.0000000000029855","article-title":"Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study","volume":"101","author":"Mazzitelli","year":"2022","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Iannone, V., Passerotto, R.A., Lamanna, F., Steiner, R.J., Lombardi, F., Salvo, P.F., Dusina, A., Farinacci, D., Borghetti, A., and Di Giambenedetto, S. (2023). Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen. Viruses, 15.","DOI":"10.3390\/v15051046"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz\/Emtricitabine\/TDF in Treatment-naive Adults with Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: Week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials","volume":"11","author":"Orkin","year":"2024","journal-title":"Lancet HIV"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (DOR\/3TC\/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0000000000000709","article-title":"Doravirine and its role in HIV treatment","volume":"17","author":"Stockdale","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/hiv.13019","article-title":"Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score","volume":"22","author":"Hsu","year":"2021","journal-title":"HIV Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate: An updated meta-analysis of 14 894 patients across 14 trials","volume":"34","author":"Pilkington","year":"2020","journal-title":"AIDS"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhang, K., Zhang, Y., Zhou, J., Xu, L., Zhou, C., Chen, G., and Huang, X. (2022). Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Na\u00efve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.676831"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/QAI.0000000000003337","article-title":"Switching to Doravirine in cART-Experienced Patients: An Effective and Highly Tolerated Option with Substantial Cost Savings","volume":"95","author":"Lanting","year":"2024","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(24)00150-4","article-title":"Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: A nationwide, matched, prospective cohort study","volume":"11","author":"Oomen","year":"2024","journal-title":"Lancet HIV"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/jac\/dkad185","article-title":"Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: A French observational study","volume":"78","author":"Perfezou","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","unstructured":"Mohavedi, R., Assoumou, L., Pozniak, A., Lacombe, K., Raffi, F., Fox, J., Roberts, D., Fletcher, C., Duffy, A., and Molina, J. (2023, January 18\u201321). Real-world retrospective observational study on the use of Doravirine (DOR) based regimens in clinical practice in Europe. Proceedings of the European AIDS Clinical Society (EACS) Conference, Warsaw, Poland."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Maggi, P., Ricci, E.D., Cicalini, S., Pellican\u00f2, G.F., Celesia, B.M., Vichi, F., Cascio, A., Sarchi, E., Orofino, G., and Squillace, N. (2023). Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08191-2"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Maggi, P., Ricci, E.D., Martinelli, C.V., De Socio, G.V., Squillace, N., Molteni, C., Masiello, A., Orofino, G., Menzaghi, B., and Bellagamba, R. (2023). Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting. Viruses, 15.","DOI":"10.3390\/v15071612"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1706\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:14Z","timestamp":1760115254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/12\/1706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ph17121706"],"URL":"https:\/\/doi.org\/10.3390\/ph17121706","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}